These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34043812)

  • 1. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
    Mo Y; Pan Y; Zhang B; Zhang J; Su Y; Liu Z; Luo M; Qin G; Kong X; Zhang R; Pan Y; Liang Y; Wang D; Wei Y; Chen H; Jiang W
    Front Immunol; 2023; 14():1298418. PubMed ID: 38239359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
    Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
    BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
    Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
    Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
    You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
    Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
    Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
    Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    Ding X; Zhang WJ; You R; Zou X; Wang ZQ; Ouyang YF; Peng L; Liu YP; Duan CY; Yang Q; Lin C; Xie YL; Chen SY; Liu YL; Gu CM; Xie RQ; Huang PY; Hong MH; Hua YJ; Chen MY
    J Clin Oncol; 2023 May; 41(14):2571-2582. PubMed ID: 36735896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
    Huang L; Zhang X; Bai Y; Chua KLM; Xie Y; Shu X; Long B; Fan C; Lim DWT; Tan SH; Wee JTS; Wang Y; Wu Y; Chua MLK
    Oral Oncol; 2021 Apr; 115():105222. PubMed ID: 33610004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.
    Tao CJ; Zhang P; Zhou L; Hu QY; Chen XZ
    Transl Cancer Res; 2020 Oct; 9(10):6392-6401. PubMed ID: 35117247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
    Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
    Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
    Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
    Front Immunol; 2021; 12():762663. PubMed ID: 34777379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
    BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.
    Lee NY; Harris J; Kim J; Garden A; Mechalakos J; Pfister DG; Chan ATC; Hu K; Colevas AD; Frank S; Shenouda G; Bar-Ad V; Waldron JN; Harari PM; Raben A; Torres-Saavedra P; Le QT
    JAMA Netw Open; 2023 Jun; 6(6):e2316094. PubMed ID: 37266942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.